PL1670769T3 - Pochodne benzimidazolu, kompozycje zawierające te związki, ich wytwarzanie i zastosowanie - Google Patents

Pochodne benzimidazolu, kompozycje zawierające te związki, ich wytwarzanie i zastosowanie

Info

Publication number
PL1670769T3
PL1670769T3 PL04768667T PL04768667T PL1670769T3 PL 1670769 T3 PL1670769 T3 PL 1670769T3 PL 04768667 T PL04768667 T PL 04768667T PL 04768667 T PL04768667 T PL 04768667T PL 1670769 T3 PL1670769 T3 PL 1670769T3
Authority
PL
Poland
Prior art keywords
preparation
compositions containing
benzimidazole derivatives
benzimidazole
derivatives
Prior art date
Application number
PL04768667T
Other languages
English (en)
Polish (pl)
Inventor
Ziping Liu
Daniel Page
Christopher Walpole
Hua Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1670769T3 publication Critical patent/PL1670769T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL04768667T 2003-09-26 2004-09-24 Pochodne benzimidazolu, kompozycje zawierające te związki, ich wytwarzanie i zastosowanie PL1670769T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0302573A SE0302573D0 (sv) 2003-09-26 2003-09-26 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP04768667A EP1670769B1 (en) 2003-09-26 2004-09-24 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
PCT/GB2004/004124 WO2005030732A1 (en) 2003-09-26 2004-09-24 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Publications (1)

Publication Number Publication Date
PL1670769T3 true PL1670769T3 (pl) 2009-09-30

Family

ID=29246982

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04768667T PL1670769T3 (pl) 2003-09-26 2004-09-24 Pochodne benzimidazolu, kompozycje zawierające te związki, ich wytwarzanie i zastosowanie

Country Status (33)

Country Link
US (1) US8633235B2 (enExample)
EP (1) EP1670769B1 (enExample)
JP (1) JP4896721B2 (enExample)
KR (1) KR101170184B1 (enExample)
CN (2) CN102010373A (enExample)
AR (1) AR045819A1 (enExample)
AT (1) ATE430135T1 (enExample)
AU (1) AU2004276062B2 (enExample)
BR (1) BRPI0414780B8 (enExample)
CA (1) CA2539738C (enExample)
CO (1) CO5680443A2 (enExample)
CY (1) CY1110332T1 (enExample)
DE (1) DE602004020907D1 (enExample)
DK (1) DK1670769T3 (enExample)
ES (1) ES2324669T3 (enExample)
HR (1) HRP20090388T1 (enExample)
IL (1) IL174215A0 (enExample)
IS (1) IS8422A (enExample)
MX (1) MXPA06003197A (enExample)
MY (1) MY140630A (enExample)
NO (1) NO20061839L (enExample)
NZ (1) NZ545736A (enExample)
PL (1) PL1670769T3 (enExample)
PT (1) PT1670769E (enExample)
RU (1) RU2346938C2 (enExample)
SA (1) SA04250310B1 (enExample)
SE (1) SE0302573D0 (enExample)
SI (1) SI1670769T1 (enExample)
TW (1) TW200521117A (enExample)
UA (1) UA86776C2 (enExample)
UY (1) UY28536A1 (enExample)
WO (1) WO2005030732A1 (enExample)
ZA (3) ZA200602446B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CN101031563A (zh) * 2004-09-24 2007-09-05 阿斯利康(瑞典)有限公司 苯并咪唑衍生物、含有它们的组合物、其制备方法和用途
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
EP1797077B1 (en) * 2004-09-24 2012-02-15 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
EP1797078A4 (en) * 2004-09-24 2009-04-01 Astrazeneca Ab BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES, PREPARATION AND USES THEREOF
BRPI0517925A (pt) 2004-11-02 2008-10-21 Pfizer derivados de sulfonil benzimidazol
EP1912930A4 (en) * 2005-07-29 2010-04-14 Astrazeneca Ab PROCESS FOR PREPARING GEMINAL ((DIFLUORCYCLOALKYL) METHYL) AMINE
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
US8236841B2 (en) * 2006-09-13 2012-08-07 Kyowa Hakko Kirin Co., Ltd. Fused heterocycle derivative
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
RU2454234C1 (ru) * 2011-03-16 2012-06-27 Константин Михайлович Аверин Соли 1,3-диэтилбензимидазолия - иммуностимулирующие средства и фармацевтические композиции на их основе
EP2864310B1 (en) * 2012-06-13 2022-10-26 Cytec Technology Corp. Stabilizer compositions containing substituted chroman compounds and methods of use
AU2013283543B2 (en) 2012-06-26 2017-11-02 Bayer Pharma Aktiengesellschaft N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN112010789A (zh) * 2019-05-31 2020-12-01 中国科学院上海药物研究所 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
GB202019335D0 (en) * 2020-12-08 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions
KR102771568B1 (ko) * 2022-03-04 2025-02-24 삼진제약주식회사 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (enExample) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
ATE303365T1 (de) * 1995-12-28 2005-09-15 Fujisawa Pharmaceutical Co Benzimidazolderivate
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
WO2001012600A1 (en) 1999-08-12 2001-02-22 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
IL148698A0 (en) 1999-09-17 2002-09-12 Cor Therapeutics Inc INHIBITORS OF FACTOR Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) * 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CN1301975C (zh) * 2000-01-14 2007-02-28 舍林股份公司 用于治疗与小胶质细胞活化有关的疾病的1,2－二芳基苯并咪唑衍生物
US7115645B2 (en) * 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
US7329679B2 (en) * 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
EP1341768A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
JP4703649B2 (ja) 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド 薬学的因子としてのピロール誘導体
US20060052421A1 (en) * 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
EP1797078A4 (en) 2004-09-24 2009-04-01 Astrazeneca Ab BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THESE DERIVATIVES, PREPARATION AND USES THEREOF
WO2006033627A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iiii
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
WO2006033629A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands
WO2006033628A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1797077B1 (en) 2004-09-24 2012-02-15 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
WO2006033632A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands I
JP2008514595A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それを含有する組成物、その製造及びその使用ｉｉ
BRPI0517925A (pt) 2004-11-02 2008-10-21 Pfizer derivados de sulfonil benzimidazol
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
TW200745049A (en) * 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) * 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds

Also Published As

Publication number Publication date
IS8422A (is) 2006-04-21
MY140630A (en) 2010-01-15
TW200521117A (en) 2005-07-01
UA86776C2 (ru) 2009-05-25
BRPI0414780B8 (pt) 2021-05-25
BRPI0414780B1 (pt) 2018-10-23
NZ545736A (en) 2009-11-27
SI1670769T1 (sl) 2009-10-31
WO2005030732A1 (en) 2005-04-07
AR045819A1 (es) 2005-11-16
EP1670769B1 (en) 2009-04-29
CA2539738A1 (en) 2005-04-07
EP1670769A1 (en) 2006-06-21
ZA200702226B (en) 2009-01-28
IL174215A0 (en) 2006-08-01
US20080207612A1 (en) 2008-08-28
CO5680443A2 (es) 2006-09-29
DK1670769T3 (da) 2009-08-10
HK1089436A1 (en) 2006-12-01
RU2346938C2 (ru) 2009-02-20
ATE430135T1 (de) 2009-05-15
JP4896721B2 (ja) 2012-03-14
KR101170184B1 (ko) 2012-07-31
ES2324669T3 (es) 2009-08-12
SE0302573D0 (sv) 2003-09-26
MXPA06003197A (es) 2006-06-23
SA04250310B1 (ar) 2009-01-19
HRP20090388T1 (hr) 2009-08-31
UY28536A1 (es) 2005-04-29
PT1670769E (pt) 2009-07-09
BRPI0414780A (pt) 2006-11-21
ZA200602446B (en) 2007-09-26
AU2004276062B2 (en) 2008-05-22
DE602004020907D1 (de) 2009-06-10
ZA200702131B (en) 2008-08-27
RU2006113371A (ru) 2007-11-10
CY1110332T1 (el) 2015-01-14
US8633235B2 (en) 2014-01-21
CN102010373A (zh) 2011-04-13
CA2539738C (en) 2011-11-22
JP2007506721A (ja) 2007-03-22
KR20070001052A (ko) 2007-01-03
AU2004276062A1 (en) 2005-04-07
NO20061839L (no) 2006-06-26
CN1886379A (zh) 2006-12-27

Similar Documents

Publication Publication Date Title
ZA200702131B (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof l
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL177533A (en) Benzimidazole derivatives, their preparation and pharmaceutical compositions comprising them
IL181683A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL179595A0 (en) Substituted indazoles, compositions containing same, preparation and use
EP1646382A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1692112A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
IL169500A0 (en) Pyrrolopyridazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL173195A0 (en) Cyclovinylazoline derivatives, their preparation and pharmaceutical compositions containing them
IL172023A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL183044A0 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
IL172222A0 (en) Aryl-heteroaromatic products, compositions comprising them and use
HUP0500871A3 (en) 5-aryltetrazole compounds, compositions thereof and their use
IL172027A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1594849A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
IL174135A0 (en) Benzimidazole acetonitrile derivatives, their preparation and and pharmaceutical compositions containing them
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
IL182811A (en) History of dicarboxamide preparations, uses and methods for their preparation
EP1675834A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them
EP1680420A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1556056A4 (en) X-Nitro Compounds, Pharmaceutical Compositions And Their Uses
EP1620092A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS